Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FQQC1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $23,688
Award facts
- Contract value 100% obligated
- $23,688.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) issued a delivery order valued at $23,688.30 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/mL syringes, awarded on January 16, 2026, with completion targeted for February 9, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected under a firm fixed-price arrangement with no set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy that authorizes the company to supply an extensive range of pharmaceutical products to support Department of Defense medical facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with the PPV-G GEN V contract representing a single-award IDC valued at $499,999,999 through December 31, 2036. The parent IDC, awarded on November 13, 2025, encompasses a 30-month base period with three 30-month option periods and enables the company to deliver branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to military healthcare operations globally. Xolair, a biologic immunosuppressant agent, represents one of the specialized pharmaceutical products within DMS Pharmaceutical Group's extensive portfolio supplied to DLA's Medical Supply Chain division.
Quick answers
Who was awarded contract SPE2DR26FQQC1?
SPE2DR26FQQC1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 16, 2026.
How much is contract SPE2DR26FQQC1 worth?
The government has obligated $23,688 on SPE2DR26FQQC1.
Is contract SPE2DR26FQQC1 an order under another contract?
Yes. SPE2DR26FQQC1 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQQC1 competed?
The extent of competition for SPE2DR26FQQC1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award